Elif Hindié1, Paolo Zanotti-Fregonara2, Michele A Quinto3, Clément Morgat2, Christophe Champion4. 1. CHU de Bordeaux, Service de Médecine Nucléaire, CNRS-UMR 5287, LabEx TRAIL, Université de Bordeaux, Pessac, France; and elif.hindie@chu-bordeaux.fr champion@cenbg.in2p3.fr. 2. CHU de Bordeaux, Service de Médecine Nucléaire, CNRS-UMR 5287, LabEx TRAIL, Université de Bordeaux, Pessac, France; and. 3. Université de Bordeaux, CNRS/IN2P3, Centre d'Etudes Nucléaires de Bordeaux Gradignan (CENBG), Gradignan, France. 4. Université de Bordeaux, CNRS/IN2P3, Centre d'Etudes Nucléaires de Bordeaux Gradignan (CENBG), Gradignan, France elif.hindie@chu-bordeaux.fr champion@cenbg.in2p3.fr.
Abstract
UNLABELLED: Radiopharmaceutical therapy, traditionally limited to refractory metastatic cancer, is being increasingly used at earlier stages, such as for treating minimal residual disease. The aim of this study was to compare the effectiveness of (90)Y, (177)Lu, (111)In, and (161)Tb at irradiating micrometastases. (90)Y and (177)Lu are widely used β(-)-emitting radionuclides. (161)Tb is a medium-energy β(-) radionuclide that is similar to (177)Lu but emits a higher percentage of conversion and Auger electrons. (111)In emits γ-photons and conversion and Auger electrons. METHODS: We used the Monte Carlo code CELLDOSE to assess electron doses from a uniform distribution of (90)Y, (177)Lu, (111)In, or (161)Tb in spheres with diameters ranging from 10 mm to 10 μm. Because these isotopes differ in electron energy per decay, the doses were compared assuming that 1 MeV was released per μm(3), which would result in 160 Gy if totally absorbed. RESULTS: In a 10-mm sphere, the doses delivered by (90)Y, (177)Lu, (111)In, and (161)Tb were 96.5, 152, 153, and 152 Gy, respectively. The doses decreased along with the decrease in sphere size, and more abruptly so for (90)Y. In a 100-μm metastasis, the dose delivered by (90)Y was only 1.36 Gy, compared with 24.5 Gy for (177)Lu, 38.9 Gy for (111)In, and 44.5 Gy for (161)Tb. In cell-sized spheres, the dose delivered by (111)In and (161)Tb was higher than that of (177)Lu. For instance, in a 10-μm cell, (177)Lu delivered 3.92 Gy, compared with 22.8 Gy for (111)In and 14.1 Gy for (161)Tb. CONCLUSION: (177)Lu, (111)In, and (161)Tb might be more appropriate than (90)Y for treating minimal residual disease. (161)Tb is a promising radionuclide because it combines the advantages of a medium-energy β(-) emission with those of Auger electrons and emits fewer photons than (111)In.
UNLABELLED: Radiopharmaceutical therapy, traditionally limited to refractory metastatic cancer, is being increasingly used at earlier stages, such as for treating minimal residual disease. The aim of this study was to compare the effectiveness of (90)Y, (177)Lu, (111)In, and (161)Tb at irradiating micrometastases. (90)Y and (177)Lu are widely used β(-)-emitting radionuclides. (161)Tb is a medium-energy β(-) radionuclide that is similar to (177)Lu but emits a higher percentage of conversion and Auger electrons. (111)In emits γ-photons and conversion and Auger electrons. METHODS: We used the Monte Carlo code CELLDOSE to assess electron doses from a uniform distribution of (90)Y, (177)Lu, (111)In, or (161)Tb in spheres with diameters ranging from 10 mm to 10 μm. Because these isotopes differ in electron energy per decay, the doses were compared assuming that 1 MeV was released per μm(3), which would result in 160 Gy if totally absorbed. RESULTS: In a 10-mm sphere, the doses delivered by (90)Y, (177)Lu, (111)In, and (161)Tb were 96.5, 152, 153, and 152 Gy, respectively. The doses decreased along with the decrease in sphere size, and more abruptly so for (90)Y. In a 100-μm metastasis, the dose delivered by (90)Y was only 1.36 Gy, compared with 24.5 Gy for (177)Lu, 38.9 Gy for (111)In, and 44.5 Gy for (161)Tb. In cell-sized spheres, the dose delivered by (111)In and (161)Tb was higher than that of (177)Lu. For instance, in a 10-μm cell, (177)Lu delivered 3.92 Gy, compared with 22.8 Gy for (111)In and 14.1 Gy for (161)Tb. CONCLUSION: (177)Lu, (111)In, and (161)Tb might be more appropriate than (90)Y for treating minimal residual disease. (161)Tb is a promising radionuclide because it combines the advantages of a medium-energy β(-) emission with those of Auger electrons and emits fewer photons than (111)In.
Authors: Richard P Baum; Aviral Singh; Harshad R Kulkarni; Peter Bernhardt; Tobias Rydén; Christiane Schuchardt; Nadezda Gracheva; Pascal V Grundler; Ulli Köster; Dirk Müller; Michael Pröhl; Jan Rijn Zeevaart; Roger Schibli; Nicholas P van der Meulen; Cristina Müller Journal: J Nucl Med Date: 2021-02-05 Impact factor: 10.057
Authors: Panagiotis J Vlachostergios; Muhammad Junaid Niaz; Myrto Skafida; Seyed Ali Mosallaie; Charlene Thomas; Paul J Christos; Joseph R Osborne; Ana M Molina; David M Nanus; Neil Harrison Bander; Scott T Tagawa Journal: Prostate Date: 2021-01-19 Impact factor: 4.104
Authors: Peter Bernhardt; Johanna Svensson; Jens Hemmingsson; Nicholas P van der Meulen; Jan Rijn Zeevaart; Mark W Konijnenberg; Cristina Müller; Jon Kindblom Journal: Cancers (Basel) Date: 2021-04-22 Impact factor: 6.639
Authors: Francesca Borgna; Stephanie Haller; Josep M Monné Rodriguez; Mihaela Ginj; Pascal V Grundler; Jan Rijn Zeevaart; Ulli Köster; Roger Schibli; Nicholas P van der Meulen; Cristina Müller Journal: Eur J Nucl Med Mol Imaging Date: 2021-10-08 Impact factor: 9.236
Authors: Kathryn M Tully; Salomon Tendler; Lukas M Carter; Sai Kiran Sharma; Zachary V Samuels; Komal Mandleywala; Joshua A Korsen; Avelyn Mae Delos Reyes; Alessandra Piersigilli; William D Travis; Triparna Sen; Nagavarakishore Pillarsetty; John T Poirier; Charles M Rudin; Jason S Lewis Journal: Clin Cancer Res Date: 2022-04-01 Impact factor: 13.801
Authors: Nadia Falzone; Nicole L Ackerman; Liset de la Fuente Rosales; Mario A Bernal; Xiaoxuan Liu; Sarah Gja Peeters; Manuel Sarmiento Soto; Aurélien Corroyer-Dulmont; Myriam Bernaudin; Elisa Grimoin; Omar Touzani; Nicola R Sibson; Katherine A Vallis Journal: Theranostics Date: 2018-01-01 Impact factor: 11.600